Amsacrine As a Topoisomerase II Poison: Importance of Drug-DNA Interactions

Overview

Journal Biochemistry

Specialty Biochemistry

Date 2012 Feb 7

PMID 22304499

Citations 26

Authors

Adam C Ketron

William A Denny

David E Graves

Neil Osheroff

Affiliations

Soon will be listed here.

Abstract

Amsacrine (m-AMSA) is an anticancer agent that displays activity against refractory acute leukemias as well as Hodgkin's and non-Hodgkin's lymphomas. The drug is comprised of an intercalative acridine moiety coupled to a 4'-amino-methanesulfon-m-anisidide headgroup. m-AMSA is historically significant in that it was the first drug demonstrated to function as a topoisomerase II poison. Although m-AMSA was designed as a DNA binding agent, the ability to intercalate does not appear to be the sole determinant of drug activity. Therefore, to more fully analyze structure-function relationships and the role of DNA binding in the action of m-AMSA, we analyzed a series of derivatives for the ability to enhance DNA cleavage mediated by human topoisomerase IIα and topoisomerase IIβ and to intercalate DNA. Results indicate that the 3'-methoxy (m-AMSA) positively affects drug function, potentially by restricting the rotation of the headgroup in a favorable orientation. Shifting the methoxy to the 2'-position (o-AMSA), which abrogates drug function, appears to increase the degree of rotational freedom of the headgroup and may impair interactions of the 1'-substituent or other portions of the headgroup within the ternary complex. Finally, the nonintercalative m-AMSA headgroup enhanced enzyme-mediated DNA cleavage when it was detached from the acridine moiety, albeit with 100-fold lower affinity. Taken together, our results suggest that much of the activity and specificity of m-AMSA as a topoisomerase II poison is embodied in the headgroup, while DNA intercalation is used primarily to increase the affinity of m-AMSA for the topoisomerase II-DNA cleavage complex.

Citing Articles

Role of Natural Binding Proteins in Therapy and Diagnostics.

Eigenfeld M, Lupp K, Schwaminger S Life (Basel). 2024; 14(5).

PMID: 38792650 PMC: 11122601. DOI: 10.3390/life14050630.

Couple-close construction of polycyclic rings from diradicals.

Long A, Oswood C, Kelly C, Bryan M, MacMillan D Nature. 2024; 628(8007):326-332.

PMID: 38480891 PMC: 11487475. DOI: 10.1038/s41586-024-07181-x.

Targeting yeast topoisomerase II by imidazo and triazoloacridinone derivatives resulting in their antifungal activity.

Rzad K, Gabriel I, Paluszkiewicz E, Kuplinska A, Olszewski M, Chylewska A Sci Rep. 2024; 14(1):3594.

PMID: 38351313 PMC: 10864382. DOI: 10.1038/s41598-024-54252-0.

Design, synthesis and biological evaluation of tetrahydroquinoxaline sulfonamide derivatives as colchicine binding site inhibitors.

Dong H, Lu L, Song X, Li Y, Zhou J, Xu Y RSC Adv. 2023; 13(43):30202-30216.

PMID: 37849704 PMC: 10577396. DOI: 10.1039/d3ra05720h.

Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis.

Elanany M, Osman E, Gedawy E, Abou-Seri S Sci Rep. 2023; 13(1):4144.

PMID: 36914702 PMC: 10011602. DOI: 10.1038/s41598-023-30885-5.

References

Herzog C, Holmes K, Tuschong L, Ganapathi R, Zwelling L . Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha. Cancer Res. 1998; 58(23):5298-300. View

Robinson M, Osheroff N . Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide. Biochemistry. 1990; 29(10):2511-5. DOI: 10.1021/bi00462a012. View

Bender R, Lehmler H, Robertson L, Ludewig G, Osheroff N . Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIalpha: altering enzyme function by blocking the N-terminal protein gate. Biochemistry. 2006; 45(33):10140-52. DOI: 10.1021/bi0524666. View

Jehn U, Heinemann V . New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA. Anticancer Res. 1991; 11(2):705-11. View

Deweese J, Osheroff N . The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res. 2008; 37(3):738-48. PMC: 2647315. DOI: 10.1093/nar/gkn937. View

Deweese J, Burgin A, Osheroff N . Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha. Biochemistry. 2008; 47(13):4129-40. PMC: 2733888. DOI: 10.1021/bi702194x. View

Bender R, Lindsey Jr R, Burden D, Osheroff N . N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Biochemistry. 2004; 43(12):3731-9. DOI: 10.1021/bi036107r. View

Bender R, Ham A, Osheroff N . Quinone-induced enhancement of DNA cleavage by human topoisomerase IIalpha: adduction of cysteine residues 392 and 405. Biochemistry. 2007; 46(10):2856-64. PMC: 2896225. DOI: 10.1021/bi062017l. View

Austin C, Marsh K, Wasserman R, Willmore E, Sayer P, Wang J . Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta. J Biol Chem. 1995; 270(26):15739-46. DOI: 10.1074/jbc.270.26.15739. View

10.

Elmore R, Wadkins R, Graves D . Cooperative binding of m-AMSA to nucleic acids. Nucleic Acids Res. 1988; 16(20):9707-19. PMC: 338774. DOI: 10.1093/nar/16.20.9707. View

11.

Fortune J, Velea L, Graves D, Utsugi T, Yamada Y, Osheroff N . DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Biochemistry. 1999; 38(47):15580-6. DOI: 10.1021/bi991792g. View

12.

Pitts S, Jablonksy M, Duca M, Dauzonne D, Monneret C, Arimondo P . Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex. Biochemistry. 2011; 50(22):5058-66. PMC: 3109987. DOI: 10.1021/bi200531q. View

13.

Chow K, Macdonald T, Ross W . DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. Mol Pharmacol. 1988; 34(4):467-73. View

14.

Baldwin E, Osheroff N . Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents. 2005; 5(4):363-72. DOI: 10.2174/1568011054222364. View

15.

Yang L, Rowe T, NELSON E, Liu L . In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin. Cell. 1985; 41(1):127-32. DOI: 10.1016/0092-8674(85)90067-4. View

16.

Pommier Y, Leo E, Zhang H, Marchand C . DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010; 17(5):421-33. PMC: 7316379. DOI: 10.1016/j.chembiol.2010.04.012. View

17.

Sorensen B, Sinding J, Andersen A, Alsner J, Jensen P, Westergaard O . Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. J Mol Biol. 1992; 228(3):778-86. DOI: 10.1016/0022-2836(92)90863-f. View

18.

Kell J . Treatment of relapsed acute myeloid leukaemia. Rev Recent Clin Trials. 2008; 1(2):103-11. DOI: 10.2174/157488706776876445. View

19.

Waring M . DNA-binding characteristics of acridinylmethanesulphonanilide drugs: comparison with antitumour properties. Eur J Cancer (1965). 1976; 12(12):995-1001. DOI: 10.1016/0014-2964(76)90066-9. View

20.

Osheroff N, Zechiedrich E . Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form. Biochemistry. 1987; 26(14):4303-9. DOI: 10.1021/bi00388a018. View